Blog
RSS FeedPosted by Michael Wonder on 07 Feb 2019
Vertex calls for changes to NICE as cystic fibrosis drug profits soar
6 February 2019 - Vertex has revealed financial figures that are likely to go down well with investors, but not ...
Posted by Michael Wonder on 07 Feb 2019
What will a no-deal Brexit mean for pharma and health care?
7 February 2019 - Britons are bracing themselves for the UK’s imminent departure from the European Union. A worst-case scenario ...
Posted by Michael Wonder on 07 Feb 2019
Diabetics in Britain worry a no-deal Brexit could put their lives at risk
6 February 2019 - Neil Macdougall has had Type 1 diabetes almost as long as he can remember. He wears ...
Posted by Michael Wonder on 07 Feb 2019
Vertex fears its triplet will also face UK reimbursement battle
6 February 2019 - Vertex Pharmaceuticals' cystic fibrosis business grew more than 40% in 2018, partially because of reimbursement victories in ...
Posted by Michael Wonder on 06 Feb 2019
NICE collaborates with the Canadian Agency for Drugs and Technology in Health to offer parallel scientific advice
6 February 2019 - NICE and the Canadian Agency for Drugs and Technology in Health have launched a new collaboration to ...
Posted by Michael Wonder on 06 Feb 2019
New opportunity: parallel scientific advice from CADTH and NICE
6 February 2019 - CADTH is pleased to announce a new collaboration with England’s NICE (National Institute for Health and ...
Posted by Michael Wonder on 04 Feb 2019
UK patient activist group takes aim at Orkambi patent
4 February 2019 - Calls to bypass patent adds to pressure on Vertex. ...
Posted by Michael Wonder on 04 Feb 2019
Mother of four is denied cancer drug that could save her life
2 February 2019 - A British nurse with four children is being denied potentially life-saving cancer treatment that was approved ...
Posted by Michael Wonder on 04 Feb 2019
Calls for action on patients denied £100,000 cystic fibrosis drug
4 February 2019 - Ministers urged to consider revoking patent on life-extending Orkambi, which NHS cannot afford. ...
Posted by Michael Wonder on 01 Feb 2019
NICE recommends another revolutionary CAR T-cell therapy for adults with lymphoma
1 February 2019 - Adults with relapsed or refractory diffuse large B-cell lymphoma will be able to access another revolutionary chimeric ...
Posted by Michael Wonder on 31 Jan 2019
Vertex an “extreme outlier” in pricing and behaviour, says NHS England
31 January 2019 - Members of parliament aim to break three year deadlock. ...
Posted by Michael Wonder on 29 Jan 2019
Novartis urges government to ‘minimise disruption’ in no-deal Brexit
28 January 2019 - Novartis has issued a statement expressing concern over the state of medicine supply to the UK, ...
Posted by Michael Wonder on 29 Jan 2019
NICE Scientific Advice launches collaborative programme with life sciences industry body
29 January 2019 - NICE has announced a collaboration with the body which represents life sciences organisations in the UK. ...
Posted by Michael Wonder on 28 Jan 2019
Cystic fibrosis patients lobby Vertex to drop drug prices
28 January 2019 - Healthcare professionals and patient groups have written to Vertex’s CEO Jeffrey Leiden in a bid to ...
Posted by Michael Wonder on 28 Jan 2019
Lords continue to call for clarity on ‘no-deal Brexit’ medicines access
28 January 2019 - As uncertainty remains on access to medicine in the event of a no-deal Brexit, Lords are ...